The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Time-of-day administration of immunotherapy in early-stage triple-negative breast cancer: Immune-dependent chronotherapy effects in the phase III A-BRAVE trial.
 
Maria Vittoria Dieci
Honoraria - AstraZeneca; daiichi-sankyo; Lilly; Menarini Group
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - reveal genomics - listed as co-inventor in patent applications for HER2DX
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Roche
 
Davide Massa
Travel, Accommodations, Expenses - Lilly; Roche
 
Elisa Gasparini
No Relationships to Disclose
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Alberto Zambelli
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Exact Sciences; Gilead Sciences; Lilly; Merck; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Daiichi Sankyo Europe GmbH; Gilead Sciences; seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly
 
Adolfo Favaretto
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Takeda
 
Michelino De Laurentiis
Stock and Other Ownership Interests - Arvinas
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Exact Sciences; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; TOMA Biosciences; Veracyte
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genzyme (Inst); Lilly; MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Federico Piacentini
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Roche; Seagen
Expert Testimony - Gilead Sciences
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Novartis; Roche
Other Relationship - Pfizer
 
Giulia Bianchi
No Relationships to Disclose
 
Claudio Zamagni
Consulting or Advisory Role - AstraZeneca; Daichi-Sankyo; EISAI; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Greenwich LifeSciences (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichi-Sankyo; Gilead Sciences; MSD Oncology; Novartis; Pfizer; Roche
 
Saverio Cinieri
No Relationships to Disclose
 
Lucia Del Mastro
Honoraria - Gilead Sciences; Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Ipsen; Lilly; Menarini; MSD; Novartis; Olema Oncology; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Olema Oncology; Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Menarini Group; Pfizer; Roche
 
Antonino Musolino
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Eisai Europe; Lilly; Novartis; seagen
Research Funding - Lilly; Roche (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Alessandra Gennari
Honoraria - Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; Novartis; Roche
Speakers' Bureau - Eisai Europe
 
Antonella Ferro
Honoraria - Astrazeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer
Consulting or Advisory Role - Lilly; Novartis
Travel, Accommodations, Expenses - Ipsen; Novartis
 
Lorenzo Nicolè
No Relationships to Disclose
 
Gian Luca De Salvo
No Relationships to Disclose
 
Stefania Lando
No Relationships to Disclose
 
Pierfranco Conte
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - co-inventor in patent applications for HER2DX
 
Valentina Guarneri
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; Menarini Group; MSD; Novartis; Olema Oncology; Pfizer; Pierre Fabre; Roche
Speakers' Bureau - Abbvie; AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Menarini Steamline; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead/Forty Seven; Menarini Group; Roche